Toshio Kubo

  • 350 Citations
  • 11 h-Index
20072019
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 44 Similar Profiles
Epidermal Growth Factor Receptor Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2019

  • 350 Citations
  • 11 h-Index
  • 60 Article

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

Harada, D., Kozuki, T., Nogami, N., Bessho, A., Hosokawa, S., Fukamatsu, N., Hotta, K., Oohashi, K., Kubo, T., Yoshioka, H., Yokoyama, T., Sone, N., Kuyama, S., Kudo, K., Yasugi, M., Takigawa, N., Oze, I. & Kiura, K., Jan 1 2019, In : Asia-Pacific Journal of Clinical Oncology.

Research output: Contribution to journalArticle

Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Nanoparticles
Appointments and Schedules

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Senoo, S., Ninomiya, T., Makimoto, G., Nishii, K., Kano, H., Watanabe, H., Hata, Y., Kubo, T., Tanaka, T., Hotta, K., Maeda, Y. & Kiura, K., Apr 1 2019, In : Internal medicine (Tokyo, Japan). 58, 7, p. 985-989 5 p.

Research output: Contribution to journalArticle

Open Access
Cell Death
Carcinoma
Lung
Neoplasms
Macrophages
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
osimertinib
Meningeal Carcinomatosis
4 Citations (Scopus)

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404

Ninomiya, T., Nogami, N., Kozuki, T., Harada, D., Kubo, T., Oohashi, K., Kuyama, S., Kudo, K., Bessho, A., Fukamatsu, N., Fujimoto, N., Aoe, K., Shibayama, T., Sugimoto, K., Takigawa, N., Hotta, K. & Kiura, K., Jan 1 2018, In : Lung Cancer. 115, p. 103-108 6 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mutation
Diarrhea
2 Citations (Scopus)

Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Hida, T., Kaji, R., Satouchi, M., Ikeda, N., Horiike, A., Nokihara, H., Seto, T., Kawakami, T., Nakagawa, S. & Kubo, T., Jul 1 2018, In : Clinical Lung Cancer. 19, 4, p. e405-e415

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
docetaxel
Confidence Intervals
Survival
Safety